The weight loss drug Mounjaro has been approved for sale in Hong Kong by Li Lai.

On October 28, Janssen Pharmaceuticals announced that it has obtained approval from the Hong Kong SAR government to sell its Tirzepatide injection (brand name: Mounjaro) in a device called Kwikpen (pre-filled injection pen) for long-term weight management and type 2 diabetes. Janssen expects to start selling this weight loss medication in Hong Kong as early as the end of this year.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments